Cardlytics (CDLX) Stock Price, News & Analysis

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CDLX shares.
View CDLX analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 1-year target prices for Cardlytics' stock. Their CDLX share price targets range from $9.00 to $18.00. On average, they anticipate the company's share price to reach $15.50 in the next twelve months. This suggests a possible upside of 36.6% from the stock's current price.
View analysts price targets for CDLX or view top-rated stocks among Wall Street analysts.

Cardlytics' stock was trading at $9.21 at the beginning of the year. Since then, CDLX stock has increased by 23.2% and is now trading at $11.35.
View the best growth stocks for 2024 here.

Cardlytics saw a increase in short interest in March. As of March 31st, there was short interest totaling 5,950,000 shares, an increase of 32.8% from the March 15th total of 4,480,000 shares. Based on an average daily trading volume, of 1,680,000 shares, the short-interest ratio is currently 3.5 days.
View Cardlytics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CDLX earnings forecast.

Cardlytics, Inc. (NASDAQ:CDLX) released its quarterly earnings data on Thursday, March, 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The firm earned $89.17 million during the quarter. Cardlytics had a negative trailing twelve-month return on equity of 25.38% and a negative net margin of 43.56%.

Invesco Dorsey Wright Technology Momentum ETF holds 380,072 shares of CDLX stock, representing 1.38% of its portfolio.

Cardlytics updated its first quarter 2024 earnings guidance on Thursday, March, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $70.0 million-$73.0 million, compared to the consensus revenue estimate of $66.5 million.

26 employees have rated Cardlytics Chief Executive Officer Lynne Laube on Glassdoor.com. Lynne Laube has an approval rating of 86% among the company's employees. 61.0% of employees surveyed would recommend working at Cardlytics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include NVIDIA (NVDA), Block (SQ), DocuSign (DOCU), Advanced Micro Devices (AMD), Caterpillar (CAT), Walt Disney (DIS), Alibaba Group (BABA), Trade Desk (TTD), QUALCOMM (QCOM) and Twilio (TWLO).

Cardlytics (CDLX) raised $76 million in an IPO on Friday, February 9th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

Cardlytics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.24%), Assenagon Asset Management S.A. (0.09%), Check Capital Management Inc. CA (0.09%) and Shikiar Asset Management Inc. (0.08%). Insiders that own company stock include Amit Gupta, Andrew Christiansen, Clifford Sosin, John V Balen, John V Balen, Karim Saad Temsamani, Kirk Somers, Lynne Marie Laube, Nicholas Hollmeyer Lynton, S Aimee Lapic, Scott D Grimes and Scott D Grimes.
View institutional ownership trends.

Shares of CDLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.